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Abstract: Depression during pregnancy occurs frequently and selective serotonin reuptake 
inhibitors (SSRIs) are often the drug of choice when treating pregnant women. Most published 
studies found no increased risks of congenital malformations in association with SSRIs, but 
there are reports of various malformations for SSRIs as a group and for specific SSRIs. To 
assess potential adverse effects of SSRIs as one group may be questioned because of their 
dissimilarities and very large datasets are needed when studying specific SSRIs. The national 
health and population registers in the Nordic countries offer excellent opportunities to assess long 
term effects of exposure during fetal life. As each of the Nordic countries is small, collaborative 
studies including information from all the Nordic countries are warranted to fully understand 
risks associated with exposure to antidepressants in fetal life.
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Selective serotonin reuptake inhibitors (SSRIs) have been used extensively for the treat-
ment of depression, including pregnant women during the last few decades. Though the 
data so far available show that SSRIs are not major teratogens, there are reports of various 
malformations for SSRIs as a group and for specific SSRIs.1–9 Moreover, as depression in 
itself might affect the fetus adversely the question whether it is safer to stop rather than 
continue medical treatment for depression when a woman becomes pregnant remains 
unsolved. Several of the antidepressants might also be used with indicators other than 
depression such as anxiety and pain conditions. In Europe and the US, the regulatory 
authorities recommend that SSRIs should only be used when the benefits outweigh 
the risks, but such recommendations are difficult to follow when the risks are not fully 
known. Consequently, well-performed studies such as the study by Kornum et al assess-
ing the safety of antidepressants during pregnancy are warranted.10 The authors present 
an updated analysis of SSRI use and risk of congenital malformations using data from 
regional and national registers in Denmark.
Depression during pregnancy occurs frequently and estimated rates vary from 
7% to 25%.11 Relapses during pregnancy have been reported to be about 50% and 
the discontinuation of medication because of anticipated risks might explain some of 
this high rate of relapse.12 Most of the women included in the study by Kornum et al 
were included between 1997 and 2006 and during this period use of SSRIs during 
pregnancy in Denmark increased from 0.3% to 2.4%. The trend of an increased use 
of SSRIs during pregnancy has been reported from other countries and the recur-
ring reports of risks with SSRIs during pregnancy seem to have had no effect on this Clinical Epidemiology 2010:2 206
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trend.13 One should also recall that although use of SSRIs 
is increasing in the general population and among pregnant 
women, major depression seems to be undertreated in general 
with only a minority with signs of major depression receiv-
ing treatment.14
Serotonin, which is mainly found in the central nervous 
system, the intestinal wall, and in large constricted blood 
vessels has a variety of functions such as effects on 
mood and behavior as well as vasoconstrictive properties. 
Depressed individuals have decreased concentration of 
serotonin metabolites in the cerebrospinal fluid and brain 
tissues. SSRIs are antidepressants that inhibit the reuptake 
of serotonin into the pre-synaptic cell and initially increase 
the level of serotonin available to bind to the post-synaptic 
receptor. In accordance with previous studies, Kornum and 
coworkers analyzed risks of SSRIs as one group (ATC-code 
N06AB), but also risks associated with specific SSRIs such as 
escitalopram, citalopram, sertraline, fluvoxamine, fluoxetine, 
and paroxetine.1–10,12 The different SSRIs have varying degree 
of selectivity for serotonin and the other monoamine trans-
porters and may vary in potency, pharmacokinetics, and 
metabolism. The acute increase in serotonin levels is prob-
ably not the whole explanation of the mechanism of action 
of SSRIs, which largely remains unknown and so does the 
mode in which SSRIs may exert their potential teratogenic 
effect. In this context it is important to note that other antide-
pressants such as clomipramine with ATC-code N06AA and 
venlafaxine (N06AX) also affect the reuptake of serotonin 
and have selectivity for serotonin. In the study by Kornum 
et al these two drugs were grouped with other non-SSRI 
antidepressants and for which they found no increased 
risks of congenital malformations.10 As the authors point 
out specific SSRIs could have different teratologic effects 
and consequently they should ideally not be evaluated as 
one entity. However, for practical reasons, and mainly due 
to limited statistical power in most of the previous studies 
SSRIs have been studied as one group. In some studies risks 
have been assessed for the specific SSRIs most frequently 
used and the reported findings with increased risks for 
cardiac malformations with paroxetine might partly reflect its 
dominant role on the market in the earlier years.1,2,5,6 Though 
citalopram was the most prevalent drug in the present study, 
use of escitalopram has increased several-fold in the Nordic 
countries during recent years. Kornum et al found a doubled 
risk for malformations in general and even higher risks for 
cardiac malformations and septal heart defects among users 
of escitalopram. As escitalopram is the active enantiomer of 
citalopram and the drugs are similar concerning reuptake 
inhibition of serotonin and selectivity for serotonin, the 
finding of no or only slightly increased risks for citalopram is 
surprising considering the increased risks with escitalopram. 
Future studies may reevaluate whether antidepressants should 
be grouped according to SSRIs or non-SSRIs, serotonin 
selectivity, or other criteria when assessing potential adverse 
effects, at least when limited power does not allow analyses 
of specific antidepressants.
As illustrated in the study by Kornum et al the national 
health and population registers in the Nordic countries 
offer excellent opportunities to assess long term effects to 
exposure during fetal life.10 Through the 10 or 11 digit code 
assigned to each citizen in the Nordic countries, included 
in the national and in some regional registers, it is possible 
to link information from different registers and thereby 
follow each individual from the beginning of life until 
death. The national registers in the Nordic countries, which 
are constructed in a similar way and with similar contents 
have been used for numerous studies and contributed to 
shed light on important scientific questions. However, with 
opportunities come responsibilities. Access to these rich 
data sources does not necessarily mean that the information 
can be used unrestricted. Rare exposures and rare outcomes 
demand very large databases and as each of the Nordic 
countries are small countries with a population ranging from 
300,000 in Iceland to 9 million in Sweden, the data in each 
country are probably too sparse to evaluate associations 
between specific drugs and specific malformations or other 
rare outcomes. The limited size of the study by Kornum and 
coworkers is only partly compensated by their comprehen-
sive analyses. Some questions such as the implication of the 
underlying psychiatric disease were left unanswered and oth-
ers would have needed a much larger dataset. A large dataset 
could have been accomplished by combining information 
from the health registers in the Nordic countries. Women 
planning a pregnancy and their physicians are entitled to 
get as reliable information as possible concerning risks with 
medication that can be used during pregnancy and this can 
only be achieved through rich data sets combined with high 
quality studies.
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